We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Assay Identifies Which Species Patients with Fish Allergy Can Tolerate

By LabMedica International staff writers
Posted on 20 Sep 2022
Print article
Image: ALEX2 is a state-of-the-art multiplex ELISA test based on proven immunoassay chemistry and detection methods (Photo courtesy of Macro Array Diagnostics)
Image: ALEX2 is a state-of-the-art multiplex ELISA test based on proven immunoassay chemistry and detection methods (Photo courtesy of Macro Array Diagnostics)

Fish allergy is an immune hypersensitivity to proteins found in fish. Symptoms can be either rapid or gradual in onset. The latter can take hours to days to appear. The former may include anaphylaxis, a potentially life-threatening condition which requires treatment with epinephrine.

Diagnostic tests for fish allergy included skin-prick tests and blood antibody tests, which are used to check for the presence of an immune protein called an anti-parvalbumin antibody, which the body produces in response to a fish allergen. If the tests aren’t conclusive, an allergist may recommend an oral food challenge.

Allergy Specialists at the University Hospital St. Pölten (St. Pölten, Austria) and their colleagues investigated whether multiplex immunoglobulin E (IgE) testing reveals potentially tolerated fish through absence of IgE to parvalbumin (PV) and extracts from specific species. Sera from a cohort that comprised 263 patients (median age, 12 years; range, 1-65; 160 of whom were males) from Austria, China, Denmark, Luxembourg, Norway and Spain with a documented clinical history of fish allergy and confirmed sensitization to fish.

The team used a research version of the ALEX2 multiplex IgE quantification assay (Macro Array Diagnostics, Vienna, Austria). Specific IgE to PVs from 10 fish species (nine bony and one cartilaginous), and to extracts from seven species was quantified. The IgE signatures of individual patients and patient groups were analyzed using SPSS and R.

The scientists reported that up to 38% of the patients were negative to cod PV, the most commonly used molecule in fish allergy diagnosis. Forty-five patients (17%) tested negative to PVs, but positive to the respective fish extracts, underlining the requirement for extracts for accurate diagnosis. Between 60% (Spain) and 90% (Luxembourg) of the patients were negative to PV and extracts from ray, a cartilaginous fish, indicating its potential tolerance. Up to 21% of the patients were negative to at least one bony fish species. Of the species analyzed, negativity to mackerel emerged as the best predictive marker of negativity to additional bony fish, such as herring and swordfish.

The team also calculated the probability that all three IgE tests would be negative for a species if tolerance to other species is known. They found patients who are negative for tuna are 92% likely to be negative for ray and swordfish. Patients who are negative for mackerel are 93% likely to be negative for herring and ray and 86% likely to be negative for swordfish.

Tanja Kalic, PhD, and Heimo Breiteneder, PhD, a professor of pathophysiology, both study authors, said, “The most commonly used fish allergen in diagnosis is cod parvalbumin, Gad m 1. In the study up to 38% of fish-allergic patients, depending on country of origin, were negative to this molecule, clearly showing that additional parvalbumins from other fish species are required in order to avoid false-negative testing of patients.”

The authors concluded that parvalbumins and extracts from multiple fish species relevant for consumption should be used in fish-allergy diagnosis, which may help identify potentially tolerated species for individual patients. The study was published on August 21, 2022 in The Journal of Allergy and Clinical Immunology: In Practice.

Related Links:
University Hospital St. Pölten
Macro Array Diagnostics 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.